Literature DB >> 16564011

A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

P Mathijs Voorhoeve1, Carlos le Sage, Mariette Schrier, Ad J M Gillis, Hans Stoop, Remco Nagel, Ying-Poi Liu, Josyanne van Duijse, Jarno Drost, Alexander Griekspoor, Eitan Zlotorynski, Norikazu Yabuta, Gabriella De Vita, Hiroshi Nojima, Leendert H J Looijenga, Reuven Agami.   

Abstract

Endogenous small RNAs (miRNAs) regulate gene expression by mechanisms conserved across metazoans. While the number of verified human miRNAs is still expanding, only few have been functionally annotated. To perform genetic screens for novel functions of miRNAs, we developed a library of vectors expressing the majority of cloned human miRNAs and created corresponding DNA barcode arrays. In a screen for miRNAs that cooperate with oncogenes in cellular transformation, we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis of primary human cells that harbor both oncogenic RAS and active wild-type p53. These miRNAs neutralize p53-mediated CDK inhibition, possibly through direct inhibition of the expression of the tumor-suppressor LATS2. We provide evidence that these miRNAs are potential novel oncogenes participating in the development of human testicular germ cell tumors by numbing the p53 pathway, thus allowing tumorigenic growth in the presence of wild-type p53.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564011     DOI: 10.1016/j.cell.2006.02.037

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  487 in total

Review 1.  Small RNAs have a big impact on regeneration.

Authors:  Elizabeth J Thatcher; James G Patton
Journal:  RNA Biol       Date:  2010-05-14       Impact factor: 4.652

2.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

3.  Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.

Authors:  Seyed H Ghaffari; Davood Bashash; Majid Zaki Dizaji; Ardeshir Ghavamzadeh; Kamran Alimoghaddam
Journal:  Tumour Biol       Date:  2011-11-10

Review 4.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

5.  Transcriptional analysis of pluripotency reveals the Hippo pathway as a barrier to reprogramming.

Authors:  Han Qin; Kathryn Blaschke; Grace Wei; Yuki Ohi; Laure Blouin; Zhongxia Qi; Jingwei Yu; Ru-Fang Yeh; Matthias Hebrok; Miguel Ramalho-Santos
Journal:  Hum Mol Genet       Date:  2012-01-27       Impact factor: 6.150

6.  Biological markers of cisplatin resistance in advanced testicular germ cell tumours.

Authors:  Adelaida García-Velasco; Ignacio Durán; Elena García; Miquel Tarón; Claudio Ballestín; Daniel Castellanos; Hernán Cortés-Funés; Luis Paz-Ares
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

7.  A simple high-throughput technology enables gain-of-function screening of human microRNAs.

Authors:  Wen-Chih Cheng; Tami J Kingsbury; Sarah J Wheelan; Curt I Civin
Journal:  Biotechniques       Date:  2013-02       Impact factor: 1.993

8.  MIR181A regulates starvation- and rapamycin-induced autophagy through targeting of ATG5.

Authors:  Kumsal Ayse Tekirdag; Gozde Korkmaz; Deniz Gulfem Ozturk; Reuven Agami; Devrim Gozuacik
Journal:  Autophagy       Date:  2013-01-15       Impact factor: 16.016

9.  Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis.

Authors:  Saskia M Wilting; Wina Verlaat; Annelieke Jaspers; Nour A Makazaji; Reuven Agami; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  Epigenetics       Date:  2013-01-16       Impact factor: 4.528

10.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

Authors:  Christian J Braun; Xin Zhang; Irina Savelyeva; Sonja Wolff; Ute M Moll; Troels Schepeler; Torben F Ørntoft; Claus L Andersen; Matthias Dobbelstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.